8 results about "Psoriasis patient" patented technology

The invention discloses a disease control state evaluation system and method based on psoriasis patient feedback, subjective feelings of patients on disease control can be captured in clinical and non-clinical scenes, and a concept framework is based on literature and doctor-patient feedback. Different from the past psoriasis PROM, the invention provides a method for comprehensively, standardly and quickly collecting'disease control 'information, and the structure content has value for clinical and scientific research. Statistical analysis shows that good clinical benefits can be obtained when the model is applied clinically, and an effective basis for individualized precise treatment is provided for improvement and self-management of psoriasis, especially chronic diseases in China.

The invention belongs to the technical field of biology, and particularly relates to a psoriasis treatment preparation and method and application. The expression of SECTM1 in the skin of a psoriasis patient is increased, an SECTM1 antibody can inhibit immune cells and relieve inflammatory response, psoriasis mice treated by the SECTM1 antibody can cause expression reduction of inflammatory factors Il6, Tnfa, Il1b, Il22 and Il17a, psoriasis skin treated by the SECTM1 antibody can cause reduction of CD7 + cell infiltration quantity, and hacat cells knock down SECTM1 gene expression so as to inhibit proliferation of skin epithelial cells, so that the SECTM1 antibody can be used for treating psoriasis mice. Therefore, the SECTM1 antibody preparation can be used for treating psoriasis, and the recurrence rate is low.

This invention provides an apremilast-loaded hydrogel of *Callicarpa nudiflora* vesicles, its preparation method, and its application, relating to the field of pharmaceutical formulation technology. This invention utilizes *Callicarpa nudiflora* vesicles to encapsulate apremilast and then reconstitute it into a hydrogel, preparing a drug that can be directly applied to the affected skin of psoriasis patients via local transdermal administration. The hydrogel achieves synergistic treatment of psoriasis through apremilast and *Callicarpa nudiflora* vesicles, improving efficacy.

The invention relates to a psoriasis diagnosis marker and a psoriasis treatment target, and relates to the technical field of biological medicines. Through systematic analysis on the number, area and diameter of lymphatic vessels and VEGF-C expression of psoriasis skin and an established mouse model, the invention reveals that VEGF-C expression in psoriasis patient skin is up-regulated, the number, area and diameter of lymphatic vessels are obviously higher than those of healthy control, and the number expression of lymphatic vessels in a mouse recurrence model is further increased; and the VEGF-C expression is further improved. The research of the invention provides a new diagnostic marker and a potential therapeutic target for psoriasis, and provides a new direction and strategy for treating psoriasis or preventing relapse of psoriasis.

The present invention relates to a biomarker composition for diagnosing psoriasis, comprising a Clostridium leptum strain as an active ingredient. It has been confirmed that the relative intestinal abundance of the strain is significantly reduced in a psoriasis patient group in comparison to that of a normal group, and the strain is effective in alleviating psoriasis symptoms and improving intestinal permeability, and thus can be effectively used as a composition for diagnosing, preventing, treating, or alleviating psoriasis.

This invention discloses the application of lupinone in the preparation of drugs for treating psoriasis, belonging to the field of pharmaceutical technology. In this invention, lupinone is used to treat psoriasis by regulating CD4 levels in psoriasis patients. + FoxP3 + The number of Tregs, regulatory T lymphocytes, reduces the expression of CD3-positive cells and the level of inflammatory factors in the skin lesions of psoriasis patients, thereby regulating the immune response of psoriasis patients and thus achieving the treatment of psoriasis. Specifically, it can reduce the severity of psoriasis, improve the degree of erythema, scaling and infiltration of skin lesions, significantly reduce the PASI (Psoriasis Area and Severity Index) score of skin lesions, reduce the thickness of the epidermis at the skin lesion site and inhibit epidermal proliferation, improve hyperkeratosis and parakeratosis, and improve acanthosis.

The present invention relates to use of C1Q and / or a subunit thereof as a target in the prevention and treatment of psoriasis. The C1QA / B / C gene expression in monocytes / macrophages in psoriatic skin lesions is enhanced, the content of C1Q subunit protein in the serum of psoriasis patients exhibits a significant difference before and after treatment, and the expression level of C1Q subunit protein in the serum of psoriasis patients after treatment is significantly reduced. In addition, the C1Q gene knockout can effectively reduce the expression of psoriasis-related inflammatory factors such as IFN-gamma and TNF in C1Q gene-knockout monocytes, indicating that by inhibiting the expression or function of C1Q, the immune response and inflammation level in psoriasis patients can be regulated, thus achieving effective prophylactic and therapeutic effects on psoriasis. Therefore, C1Q can be used as a biological treatment target for psoriasis to prepare a medicament for the prevention and treatment of psoriasis.

The application discloses application of anti-IGFBP7 antibodies in treating skin diseases, belongs to the technical field of psoriasis treatment, and discloses application of anti-IGFBP7 antibodies in preparation of a medicament for treating psoriasis, wherein the medicament is used for reducing and treating psoriasis-like inflammation by inhibiting expression of IGFBP7 in blood vessels of skin of a psoriasis patient. After the anti-IGFBP7 antibodies are used, psoriasis inflammation is reduced, meanwhile, epidermal thickness of a psoriasis patient is reduced, erythema formation is inhibited, and the generation of scales is reduced. In protecting vascular barrier function and treating psoriasis, the anti-IGFBP7 antibodies have a good medicinal prospect.